在慢性期接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中，sVCAM-1 和 TGFβ1。
sVCAM-1, and TGFβ1 in chronic phase, chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
机构信息
Department of Internal Medicine & Hematology Unit, Assiut University Hospitals and South Egypt Cancer Institute Bone Marrow Transplantation Unit, Assiut University, Assiut, Egypt.
Department of Internal Medicine & Hematology Unit, Assiut University Hospitals, Assiut University, Assiut, Egypt.
出版信息
Egypt J Immunol. 2022 Oct;29(4):163-173.
The outcome for chronic phase (CP) chronic myelogenous leukemia (CML) patients has changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy. We examined the characteristics of CML patients during TKI therapy by determining the plasma concentrations of soluble vascular cell adhesion molecule 1 (sVCAM-1), and transforming growth factor (TGFβ1) biomarkers. The plasma levels of sVCAM-1 and TGFβ1 were measured by ELISA at baseline and after 3 months of TKI treatment. The levels of sVCAM-1, and TGFβ1 were significantly elevated in patients with CML (P< 0.01). Dasatinib treatment was associated with a significant reduction in the levels of these biomarkers (P< 0.01). In conclusion, plasma levels of sVCAM-1 and TGFβ1 could have a role in the pathogenesis of CML and may be used as predictors of hematological and molecular responses to TKIs. A favorable outcome for Dasatinib therapy was observed.
自酪氨酸激酶抑制剂（TKI）治疗问世以来，慢性期（CP）慢性髓性白血病（CML）患者的预后发生了巨大变化。我们通过测定可溶性血管细胞黏附分子 1（sVCAM-1）和转化生长因子（TGFβ1）生物标志物，来研究 TKI 治疗期间 CML 患者的特征。在基线和 TKI 治疗 3 个月后，通过 ELISA 法测定 sVCAM-1 和 TGFβ1 的血浆浓度。CML 患者的 sVCAM-1 和 TGFβ1 水平显著升高（P<0.01）。达沙替尼治疗与这些生物标志物水平的显著降低相关（P<0.01）。总之，sVCAM-1 和 TGFβ1 的血浆水平可能在 CML 的发病机制中起作用，并可作为 TKI 治疗血液学和分子反应的预测因子。观察到达沙替尼治疗有良好的效果。
Zotero 插件